What the Study Found (In Plain English)
Published in Seizure (2025), this phase iii randomized trial evaluating 80 human participants investigated: There is a paucity of evidence regarding the best treatment options for children with infantile epileptic spasm syndrome who have failed the first-line treatments, i.e. Key clinical takeaway: MAD proved to be more effective than Topiramate in managing epileptic spasms refractory to first-line treatment. However, further studies with larger sample sizes and longer follow-up periods are required to generalize the findings.
Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers
Primary Endpoint & Quantitative Summary (Seizure, 2025-09-15; N = 80; Rigor 82/100): MAD proved to be more effective than Topiramate in managing epileptic spasms refractory to first-line treatment. However, further studies with larger sample sizes and longer follow-up periods are required to generalize the findings.
Study Limitations & Caveats Before You Act
Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.